Data for Riociguat presented at the CHEST 2012 Annual Meeting

October 20 - 25, 2012
Atlanta, Georgia, USA

Findings from two Phase III studies evaluating Riociguat in chronic thromboembolic pulmonary hypertension (CTEPH) and in pulmonary arterial hypertension (PAH) were presented in the late-breaking abstracts session on October 23, 2012 from 4:30 – 5:45 p.m. EDT at the 2012 American College of Chest Physicians (ACCP) annual meeting (CHEST 2012) in Atlanta, USA.

On this occasion we hosted a conference call for investors and analysts on October 24, 2012 at approx. 1:00 p.m. CEST (11:00 a.m. GMT).


Oktober 24, 2012: Investor Conference Call on Riociguat

with
Dr. Kemal Malik, Head of Global Development at Bayer HealthCare Pharmaceuticals
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations

MP3 audio recording (presentation and discussion)

TranscriptDownload (PDF, 131 KB) collect
Last updated: December 04, 2013 Copyright © Bayer AG